Preliminary Program
Stream 2: Immuno-Oncology
|
Forum 2-1: Cancer Vaccines |
|
|
Day 2: Morning, May 09, 2023 |
|
|
Chair |
Dr. Yan Leyfman, Director of Immunology Division, WACEM-ACAIM COVID-19 Taskforce, USA |
|
Co-chair |
Call for Co-chair |
|
Time |
Speeches and Speakers |
|
08:30-08:35 |
Chair’s Introduction |
|
08:35-09:00 |
Speech Opportunity Available |
|
09:00-09:25 |
Speech Opportunity Available |
|
09:25-09:50 |
Speech Opportunity Available |
|
09:50-10:15 |
Title: Nimotuzumab: Progress in Treating Patients with Pancreatic Cancer Dr. Xianhong Bai, Presideng & General Manager, Biotech Pharmaceutical Co., Ltd, China |
|
10:15-10:30 |
Coffee Break |
|
10:30-10:55 |
Speech Opportunity Available |
|
10:55-11:20 |
Speech Opportunity Available |
|
11:20-11:45 |
Speech Opportunity Available |
|
11:45-12:10 |
Speech Opportunity Available |
|
Forum 2-2: Breaking Research in Immuno-Oncology Targets |
|
|
Day 2: Morning, May 09, 2023 |
|
|
Chair |
Call for Chair |
|
Co-chair |
Call for Co-chair |
|
Time |
Speeches and Speakers |
|
08:30-08:35 |
Chair’s Introduction |
|
08:35-09:00 |
Title: Identification of Predictive Factors for Early Relapse in Patients with Unresectable Stage III NSCLC Receiving Consolidation Durvalumab After Concurrent Chemoradiation Dr. Hye Seon Kang, Assistant Professor, The Catholic University of Korea, South Korea |
|
09:00-09:25 |
Speech Opportunity Available |
|
09:25-09:50 |
Speech Opportunity Available |
|
09:50-10:15 |
Title: Target Therapy Biomarkers Screening and Potential Drug Resistance Mechanisms of Target Therapy in Neurofibromatosis Type 1 Patients Dr. Zhichao Wang, Associate Professor, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, China |
|
10:15-10:30 |
Coffee Break |
|
10:30-10:55 |
Speech Opportunity Available |
|
10:55-11:20 |
Speech Opportunity Available |
|
11:20-11:45 |
Speech Opportunity Available |
|
11:45-12:10 |
Speech Opportunity Available |
|
Forum 2-3: Checkpoint Blockade, TIGIT, PD-L1/PD-L1 |
|
|
Day 2: Morning, May 09, 2023 |
|
|
Chair |
Call for Chair |
|
Co-chair |
Call for Co-chair |
|
Time |
Speeches and Speakers |
|
08:30-08:35 |
Chair’s Introduction |
|
08:35-09:00 |
Title: TB |
|
09:00-09:25 |
Speech Opportunity Available |
|
09:25-09:50 |
Speech Opportunity Available |
|
09:50-10:15 |
Title: TB |
|
10:15-10:30 |
Coffee Break |
|
10:30-10:55 |
Dr. Saif Ullah Afridi, Postdoc Research fellow, Chinese Academy of Sciences (IPS-CAS) & Guangzhou Women and Children Medical Center (GWCMC), China |
|
10:55-11:20 |
Speech Opportunity Available |
|
11:20-11:45 |
Speech Opportunity Available |
|
11:45-12:10 |
Speech Opportunity Available |
|
Forum 2-4: Novel Anticancer Antibodies |
|
|
Day 2: Afternoon, May 09, 2023 |
|
|
Chair |
Call for Chair |
|
Co-chair |
Call for Co-chair |
|
Time |
Speeches and Speakers |
|
13:30-13:35 |
Chair’s Introduction |
|
13:35-14:05 |
Title: TBD Dr. Laura Bover, Director Monoclonal Antibody Core Facility, University of Texas M.D.Anderson Cancer Center, USA |
|
14:05-14:30 |
Title: Bispecific Nanobody for Cancer Immunotherapy Dr. Seung-Yong Seong, Department of Microbiology and Immunology, Wide River Institute of Immunology, Seoul National University College of Medicine, Korea |
|
14:30-14:55 |
Speech Opportunity Available |
|
14:55-15:20 |
Speech Opportunity Available |
|
15:20-15:35 |
Coffee Break |
|
15:35-16:00 |
Speech Opportunity Available |
|
16:00-16:25 |
Speech Opportunity Available |
|
16:25-16:50 |
Speech Opportunity Available |
|
16:50-17:15 |
Speech Opportunity Available |
|
Forum 2-5: Adoptive Cell Therapy, CARs, TILs, TCRs and CAR T’s Dysfunction |
|
|
Day 2: Afternoon, May 09, 2023 |
|
|
Chair |
Call for Chair |
|
Co-chair |
Call for Co-chair |
|
Time |
Speeches and Speakers |
|
13:30-13:35 |
Chair’s Introduction |
|
13:35-14:05 |
Title: Overcoming the Immune Barrier for "off the shel" Allogeneic CAR T Cells Dr. Sonja Schrepfer, Professor of Surgery, University of California San Francisco, USA |
|
14:05-14:30 |
Title: TBD Dr. Heinz Lubenau, CEO, Vaximm AG, Germany |
|
14:30-14:55 |
Title: TBD Dr. Manel Juan, Head of Seccion of Immunopathology, SJD Barcelona Children’s Hospital and Hospital Clínic, Spain |
|
14:55-15:20 |
Title: TBD Dr. Zhenlong Ye, Director, Shanghai Baize Medical Laboratory, Shanghai Engineering Research Center for Cell Therapy, China |
|
15:20-15:35 |
Coffee Break |
|
15:35-16:00 |
Title: TBD Dr. Jianqiang Li, Founder & CSO, HeBei Senlang Biotechnology Inc. Ltd., China |
|
16:00-16:25 |
Speech Opportunity Available |
|
16:25-16:50 |
Speech Opportunity Available |
|
16:50-17:15 |
Speech Opportunity Available |
|
Forum 2-6: IO Biomarkers |
|
|
Day 2: Afternoon, May 09, 2023 |
|
|
Chair |
Call for Chair |
|
Co-chair |
Call for Co-chair |
|
Time |
Speeches and Speakers |
|
13:30-13:35 |
Chair’s Introduction |
|
13:35-14:05 |
Speech Opportunity Available |
|
14:05-14:30 |
Speech Opportunity Available |
|
14:30-14:55 |
Speech Opportunity Available |
|
14:55-15:20 |
Speech Opportunity Available |
|
15:20-15:35 |
Coffee Break |
|
15:35-16:00 |
Speech Opportunity Available |
|
16:00-16:25 |
Speech Opportunity Available |
|
16:25-16:50 |
Speech Opportunity Available |
|
16:50-17:15 |
Speech Opportunity Available |
|
Forum 2-7: Oncolytic Virus Immunotherapy |
|
|
Day 3: Morning, May 10, 2023 |
|
|
Chair |
Dr. Ashok Srivastava, Chief Medical officer, Immuno-Oncology, Hematology and Oncolytic Virus Therapy, Trans Atlantic Therapeutics, USA |
|
Co-chair |
Call for Co-chair |
|
Time |
Speeches and Speakers |
|
08:30-08:35 |
Chair’s Introduction |
|
08:35-09:15 |
Title: Personalized Immune Therapy of Human Cancer Patients with Oncolytic Vaccinia Virus Infected , Autologous
Stem Cell Implants Dr. Aladar A. Szalay, Professor, University of Wuerzburg, Germany |
|
09:15-09:40 |
Title: Oncolytic Virus Therapy for the Treatment of Metastatic Triple Negative Breast Cancer with an Oncolytic Virus in Combination with Anti-PD-L1 and Paclitaxel and Its Response Dr. Ashok Srivastava, Chief Medical officer, Immuno-Oncology, Hematology and Oncolytic Virus Therapy, Trans Atlantic Therapeutics, USA |
|
09:40-10:05 |
Speech Opportunity Available |
|
10:05-10:30 |
Speech Opportunity Available |
|
10:30-10:45 |
Coffee Break |
|
10:45-11:10 |
Speech Opportunity Available |
|
11:10-11:35 |
Speech Opportunity Available |
|
11:35-12:00 |
Speech Opportunity Available |
|
12:00-12:25 |
Speech Opportunity Available |
|
Forum 2-8: IO Therapy Combination and Cancer Vaccine |
|
|
Day 3: Morning, May 10, 2023 |
|
|
Chair |
Call for Chair |
|
Co-chair |
Call for Co-chair |
|
Time |
Speeches and Speakers |
|
08:30-08:35 |
Chair’s Introduction |
|
08:35-09:00 |
Title: Development of Precision Semiallogeneic Cancer Vaccines for Glioblastomas Dr. Mark S. Kindy, Professor, University of South Florida, USA
|
|
09:00-09:25 |
Speech Opportunity Available |
|
09:25-09:50 |
Speech Opportunity Available |
|
09:50-10:15 |
Speech Opportunity Available |
|
10:15-10:30 |
Coffee Break |
|
10:30-10:55 |
Speech Opportunity Available |
|
10:55-11:20 |
Speech Opportunity Available |
|
11:20-11:45 |
Speech Opportunity Available |
|
11:45-12:10 |
Speech Opportunity Available |
|
Forum 2-9: Next Generation Cancer Immunotherapy and Translational Medicine |
|
|
Day 3: Morning, May 10, 2023 |
|
|
Chair |
Call for Chair |
|
Co-chair |
Call for Co-chair |
|
Time |
Speeches and Speakers |
|
08:30-08:35 |
Chair’s Introduction |
|
08:35-09:00 |
Speech Opportunity Available |
|
09:00-09:25 |
Title: TB |
|
09:25-09:50 |
Title: TB |
|
09:50-10:15 |
Speech Opportunity Available |
|
10:15-10:30 |
Coffee Break |
|
10:30-10:55 |
Speech Opportunity Available |
|
10:55-11:20 |
Speech Opportunity Available |
|
11:20-11:45 |
Speech Opportunity Available |
|
11:45-12:10 |
Speech Opportunity Available |
Contact Us: Email:Mandy@bitcongress.com
Company Name: 3F, Building 2, Dalian Life Science Innovation Center, 43 Huoju Road,
Hi-tech Industrial Zone, Dalian City, Liaoning Province, China
Copyright © 2008-2022 BIT Congress